Hong Kong has the potential to act as the command centre for China’s biotechnology innovation network, but could do with more government support to bridge the academia and industry, according to SinoMab Bioscience. The Hong Kong company is the city’s first home-grown biotech firm to go public under revamped market listing rules.
